You are here: Industry Insights > Takeda

News List

Takeda acquires PvP Biologics following coeliac disease drug trial europeanpharmaceuticalreview
March 03, 2020
A statement by the Takeda reveals the company has acquired PvP as part of a development and option agreement for the drug TAK-062.
Takeda Divests Assets to Hypera for $825M contractpharma
March 03, 2020
Portfolio includes OTC and prescription pharmaceutical products from Takeda's Growth & Emerging Markets BU.
Takeda partners Charles River to develop preclinical candidates pharmaceutical-technology
January 16, 2020
Takeda Pharmaceutical Company has teamed up with Charles River to deliver preclinical candidates across its four core therapeutic areas. Under the multi-year drug discovery collaboration, the two companies will work on multiple integrated programmes for o
Takeda, Turnstone Biologics to develop novel viral immunotherapies biospectrumasia
December 22, 2019
Turnstone and Takeda to co-develop and co-commercialize RIVAL-01, the lead candidate from Turnstone’s proprietary vaccinia virus platform, with a 50:50 global profit share
NICE recommends Takeda’s Takhzyro in hereditary angioedema pharmaceutical-technology
September 25, 2019
The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended the use of subcutaneous injection of Takeda’s Takhzyro (lanadelumab) to prevent recurrent attacks ...
Takeda and Lundbeck’s Trintellix approved in Japan for depression pharmaceutical-technology
September 25, 2019
Takeda has announced that its drug Trintellix (vortioxetine) has been approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of depression and depressed state.
Evotec, Takeda Enter Multi-Year Drug Discovery Pact contractpharma
September 25, 2019
Evotec SE has entered a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical Co. Ltd. to establish at least five drug discovery programs with the goal of Evotec delivering clinical candidates ...
Takeda receives Ministry approval for depression drug biospectrumasia
September 23, 2019
Vortioxetine is already approved in 83 countries, including US, Europe, Canada, Chile, China, Mexico, Argentina, South Korea, Turkey, Australia, Hong Kong, S.A.R., China, Singapore and South Africa.
Takeda Issues US Recall of NATPARA americanpharmaceuticalreview
September 09, 2019
Takeda Pharmaceutical announced the company is issuing a US recall for all doses of NATPARA® (parathyroid hormone) for Injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg).
Takeda recalls eye drug Natpara but warns patients not to abruptly stop treatment fiercepharma
September 08, 2019
Takeda Pharmaceutical’s been looking for a buyer for Natpara to provide some debt relief, but it has just run into some complicating circumstances. It is having to recall the eye drug from the market, a move it says may be very challenging for patients.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page